The COVID-19 pandemic has brought aerosol-related diseases to the forefront of the healthcare conversation. Health systems and GI practices alike continue to grapple with the best ways to diagnose and treat patients in a specialized, affordable, and safe manner. As telehealth and virtual visits become a mainstay in the healthcare delivery model, so must the consideration of at-home diagnostics, especially for aerosol-generating procedures like GI breath testing.
During a 30-minute virtual fireside chat, Dr. Ziad Gellad (Duke University School of Medicine and Duke University Medical Center) discussed his experience shifting from a point-of-care breath test model to at-home breath testing during the pandemic. Moderated by Craig S. Strasnick, President & CEO of CDI, Dr. Gellad also weighed in on both the clinical and financial impact on GI practices.
New Guide Available: A Pro-Forma Comparison of Breath Testing Models for Gastrointestinal Disorders
Functional GI Diagnostic Test Orders
Submit your patient diagnostic orders. We will process your order ASAP!
Latest News & Insights
CDI Joins SAM.gov as an Approved Vendor, Expanding Access to Government and Veterans’ Healthcare Networks
We are excited to announce that Commonwealth Diagnostics International (CDI) is now an approved System for Award Management (SAM.gov) vendor.…
Episode 5 of the Modern Gastro Podcast
Advancing GI Diagnostics with Functional Gut Clinic and CDI: A Conversation with Dr. Anthony Hobson In a recent conversation…
CDI Expands In-Network Coverage with Premera Blue Cross
SALEM, Mass. — Commonwealth Diagnostics International (CDI) proudly announces a new in-network agreement with Premera Blue Cross, expanding access to…
